Rapport Therapeutics (RAPP) said Monday it started an underwritten public offering of $250 million of shares, subject to market conditions.

Underwriters will be given a 30-day option to buy up to an additional $37.5 million of shares, the company said.

The company's shares were down 1.5% in recent after-hours activity.